Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
复制标题
DOI：
10.1210/jc.2011-3213
复制
发表时间：
2012-09-01
影响因子：
5.8
通讯作者：
Stalenhoef, Anton F. H.
中科院分区：
文献类型：
--
作者：
Berglund, Lars;Brunzell, John D.;Stalenhoef, Anton F. H.
目的：其目的是制定临床实践指南hyperglycidemias.Participants：该工作组包括一个由内分泌学会临床指南小组委员会（CGS），五个额外的专家在该领域选择的椅子，和一个方法学家。共识过程：共识是由系统的证据审查、电子邮件讨论、电话会议和一次面对面会议指导的。该指南由内分泌学会的CGS和临床事务核心委员会、成员回应网络帖子和内分泌学会理事会依次审查和批准。在每个阶段，工作队都根据书面意见作出修改。特别工作组建议，高甘油三酯血症的诊断应基于空腹水平，轻度和中度高甘油三酯血症（甘油三酯为150-999 mg/dl），以帮助评估心血管风险，重度和极重度高甘油三酯血症（甘油三酯> 1000 mg/dl）被认为是胰腺炎的风险。工作组还建议对高脂血症患者进行高脂血症继发性病因评估，并对原发性高脂血症受试者进行血脂异常和心血管疾病家族史评估。工作组建议中度高胆固醇血症患者的治疗目标是符合国家胆固醇教育计划成人治疗小组指南的非高密度脂蛋白胆固醇水平。最初的治疗应该是生活方式疗法;也可以考虑饮食调整和药物治疗的结合。对于重度或极重度高胆固醇血症患者，贝特类药物应作为一线药物。（J Clin Endocrinol Metab 97：2969-2989，2012）
Objective: The aim was to develop clinical practice guidelines on hypertriglyceridemia.Participants: The Task Force included a chair selected by The Endocrine Society Clinical Guidelines Subcommittee(CGS), five additional experts in the field, and a methodologist. The authors received no corporate funding or remuneration.Consensus Process: Consensus was guided by systematic reviews of evidence, e-mail discussion, conference calls, and one in-person meeting. The guidelines were reviewed and approved sequentially by The Endocrine Society's CGS and Clinical Affairs Core Committee, members responding to a web posting, and The Endocrine Society Council. At each stage, the Task Force incorporated changes in response to written comments.Conclusions: The Task Force recommends that the diagnosis of hypertriglyceridemia be based on fasting levels, that mild and moderate hypertriglyceridemia (triglycerides of 150-999 mg/dl) be diagnosed to aid in the evaluation of cardiovascular risk, and that severe and very severe hypertriglyceridemia (triglycerides of > 1000 mg/dl) be considered a risk for pancreatitis. The Task Force also recommends that patients with hypertriglyceridemia be evaluated for secondary causes of hyperlipidemia and that subjects with primary hypertriglyceridemia be evaluated for family history of dyslipidemia and cardiovascular disease. The Task Force recommends that the treatment goal in patients with moderate hypertriglyceridemia be a non-high-density lipoprotein cholesterol level in agreement with National Cholesterol Education Program Adult Treatment Panel guidelines. The initial treatment should be lifestyle therapy; a combination of diet modification and drug therapy may also be considered. In patients with severe or very severe hypertriglyceridemia, a fibrate should be used as a first-line agent. (J Clin Endocrinol Metab 97: 2969-2989, 2012)